Intellectual Property and the Availability of Pharmaceuticals in Poor Countries - Working Paper 5
Publication Info
Publication Type
Download
Research Topics
Rights and Permissions
We welcome the use of CGD work-just let us know in advance! For contact information see our Rights & Permissions page. CGD rights and permissions are managed under the terms of the Creative Commons license below.
Jean Olson Lanjouw
04/01/2002
There continues to be widespread criticism of the extension of patent rights on pharmaceuticals in the developing world as required by World Trade Organization membership. This paper examines arguments in favor and against this strengthening of worldwide patent protection. It emphasizes that these new pharmaceutical patents promise benefits and costs that differ with the characteristics of diseases. Some diseases primarily affect poor countries. For these diseases, patents will not be sufficient to attract substantial private investment because purchasing power is low. However, globally available and well-defined patent rights could increase the benefits derived from greater public financing of research on pharmaceutical products for the developing world. For major global diseases the justification for extending patents in poorer countries is less clear. Thus the optimal global framework for pharmaceutical patents might require differentiating the protection given to products in accordance with their extremely different global markets. The paper considers standard intellectual property and regulatory mechanisms that could be used to differentiate protection. All have serious drawbacks. It then describes a new mechanism that would make differentiating protection a more feasible policy option.